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Pancreatic β cellReg (regenerating gene) product, Reg protein, is induced in pancreatic β-cells and acts as autocrine/paracrine
growth factor for regeneration via the cell surface Reg receptor. However, high concentrations of Reg I protein
induced β-cell apoptosis. In the present study, we found that hepatocyte growth factor (HGF) attenuated the
β-cell apoptosis induced by the high concentrations of Reg I protein and that the combined stimulation of
interleukin-6 (IL-6) and dexamethasone (Dx) induced the accumulation of HGF mRNA as well as Reg I mRNA
in β-cells. The accumulation of the HGFmRNA was caused by the activation of the HGF promoter. Deletion anal-
ysis revealed that the region of−96 to−92 of the HGF gene was responsible for the promoter activation by IL-
6 + Dx. The promoters contain a consensus transcription factor binding sequence for signal transducer and
activator of transcription (STAT). Site-directed mutations of STAT-binding motif in the region markedly attenu-
ated theHGF promoter activity. Chromatin immunoprecipitation assay showed that STAT3 is located at the active
HGF promoter in response to IL-6 + Dx stimulation. These results strongly suggest that the combined stimula-
tion of IL-6 and glucocorticoids induces the activation of both Reg and HGF genes and that the anti-apoptotic ef-
fects of HGF against the Reg I-induced apoptosis may help β-cell regeneration by Reg I protein.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
A limited capacity for regeneration in adult β cells is thought to be a
predisposing factor for the development of diabetes [1–3]. Thus, strate-
gies for introducing the replication and growth of the β cells mass are
important for the prevention and/or treatment of diabetes [2]. We
established a model for islet regeneration in 90% depancreatized ratsatin immunoprecipitation; Dx,
hyde-3-phosphate dehydroge-
factor; HSF-2, heart shock factor
n-obese diabetic mouse; Nrf-2,
polymerase; Reg, regenerating
action; STAT, signal transducer
enyl)-2-(4-nitrophenyl)-2H-5-
y, Nara Medical University, 840
4 22 3051x2227; fax: +81 744
wa).
ights reserved.by the administration of poly(ADP-ribose) polymerase (PARP) inhib-
itors such as nicotinamide (NA) and 3-aminobenzamide (3AB) [4]. By
screening a regenerating islet-derived cDNA library, we isolated a novel
gene, Reg (regenerating gene), speciﬁcally expressed in regenerating is-
lets [5] and found that both rat and human Reg protein (rat Reg I and
human REG Iα [6,7]) induced the proliferation of β cells to ameliorate
the diabetes of 90% depancreatized rats [8] and of non-obese diabetes
(NOD) mice [9,10]. Recently, we revealed that the Reg I gene transcrip-
tion was activated by the combined addition of interleukin-6 (IL-6)
and dexamethasone (Dx) in β cells and that PARP inhibitors such as
NA and 3AB further enhanced the expression [11]. We also found that
high concentrations of Reg I protein (300–1000 nM) induced β cell apo-
ptosis via Reg receptor [12]. Thus,we assumed that the Reg–Reg receptor
system could regulate both the proliferation and apoptosis of pancreatic
β cells to maintain the insulin-producing cell mass by controlling the
concentrations of Reg I protein [2].
Accumulating evidence indicates that hepatocyte growth factor
(HGF) is an anti-apoptotic as well as amitogenic and insulinotropic fac-
tor for pancreatic β cells [13–16]: HGF was reported to protect insulin-
producing rat RINm5F β cells against free fatty acid-induced apoptosis
2989K. Nakagawa et al. / Biochimica et Biophysica Acta 1833 (2013) 2988–2995by counteracting oxidative stress [13]. From the ﬁndings, we conceived
a possibility that HGF inhibits the high concentration of Reg I protein-
induced apoptosis. In the present study, we tested the possibility and
found that HGF inhibited the pancreatic β cell apoptosis induced by
the high concentrations of Reg I protein and that the combined stimula-
tion of IL-6 and Dx induced the HGF transcription via signal transducer
and activator of transcription (STAT) binding sequence in pancreatic β
cells.
2. Materials and methods
2.1. Cell culture
RINm5F cells, a rat β cell line, were maintained as described
[11,12,17–19]. For the stimulation experiments, cells were treated
with 20 ng/ml human IL-6 (Genzyme, Cambridge, MA), 100 nM Dx
(Sigma-Aldrich, St. Louis, MO), 10 mMNA, 1 mM3AB, 25 ng/ml recom-
binant human HGF (Genzyme), 1000 nM rat Reg I protein or combina-
tions thereof [11]. Pancreatic islets were isolated by collagenase
digestion method [20,21] from male Wistar rats (200–300 g), trans-
ferred to 6-well culture dishes in groups of 200 islets, and stimulated
by the combined addition of IL-6 + Dx. 1.1B4 cells, a human pancreatic
β cell line, were purchased from European Collection of Cell Culture
(Salisbury, UK) and were maintained as described [22].
2.2. Measurement of apoptosis
Rat Reg I protein was expressed in Pichia pastoris and puriﬁed to
homogeneity using cation exchange column chromatography as de-
scribed [11,12,17]. RINm5F cells were cultured in RPMI 1640 with 1%
FCS in the presence of 1000 nM rat Reg I protein with other stimulants
for 24 h. Apoptosis was detected by the TUNEL method using an apo-
ptosis screening kit (Wako Pure Chemical, Osaka, Japan) as described
[12,19].
2.3. Measurement of viable cell numbers by tetrazolium salt cleavage
After a 24-h incubation of the RINm5F cells (5 × 104 cells/well) in
RPMI 1640 with 1% FCS in the presence of stimulants, a solution
containing 4[-3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-
1,3-benzene disulfonate (WST-1, F. Hoffmann-La Roche Ltd, Basel,
Switzerland) was added to the medium, and the cells were incubated
for another 30 min as described [11,12,23].
2.4. Induction of HGF messenger RNA
After a 24-h incubation with various stimulants, cells were harvest-
ed, and total RNAwas prepared as described [19]. Reverse transcription-
polymerase chain reaction (RT-PCR) was performed using primers cor-
responding to nucleotides 1556–1575 and 2208–2227 of ratHGFmRNA
[24], and 135–155 and 951–971 for rat glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) mRNA as described [18]. Real-time RT-PCR
was performed as described [19,25]. In brief, the cDNAwas synthesized
from total RNA as template using a High Capacity cDNA Reverse Tran-
scription kit (Applied Biosystems, Foster City, CA) for template of real-
time PCR and real-time PCR was performed using Fast SYBR® Green
Master Mix (Applied Biosystems) and Thermal Cycler Dice® Real Time
System (Takara Bio Inc., Otsu, Japan). PCR primers corresponding
to nucleotides 2145–2167 and 2235–2254 of human HGF mRNA
(NM_000601), and 420–437 and 492–509 for human β-actin mRNA
(NM_001101) were synthesized by NGRL (Sendai, Japan). Target cDNAs
were cloned into pBluescript SK(-) plasmid (Stratagene, La Jolla, CA)
and sequential 10-fold dilutions from 102–107 copies/μL were pre-
pared. The serial dilutions were run to verify the speciﬁcity and to test
the sensitivity of the SYBR Green-based real-time RT-PCR. HGF mRNA
value was normalized to that of β-actin mRNA, which was used toaccount for differences in the efﬁciency of reverse transcription be-
tween samples.
2.5. Measurement of HGF protein in culture medium
RINm5F cells were cultured in RPMI 1640 with 1% FCS in the
presence of stimulants for 24 h. The concentration of HGF protein in
the medium was measured by using a rat HGF EIA kit (Institute of Im-
munology, Tokyo, Japan) according to the instructions of the supplier.
2.6. Construction of reporter plasmid and luciferase assay
A 1395-bp genomic fragment containing the 5′-ﬂanking region of
the rat HGF gene (−1336 to +59) [26] was inserted into pGL3-Basic
vector (Promega, Madison, WI). Unidirectional deletions were made
using a Deletion Kit for Kilo-Sequencing (Takara Bio Inc.). Mutants of
potential binding sites for Stat and GATA factors (STAT-M1, STAT-M2,
GATA-M)were constructed on pGL3 vector containing theHGF promot-
er by PCR. Promoter plasmidwas transfected into RINm5F cells by using
DMRIE-C (Invitrogen Corp., Carlsbad, CA) as described [11,18]. In brief,
RINm5F cells were seeded at 1 × 105 cells per well in a 24-well dish
in RPMI1640 supplemented with 10% FCS. After 24 h, the medium of
each well was replaced with fresh medium containing stimulants and
incubated further for 24 h. Cells were harvested in 1 ml of ice-cold
PBS, washed twice with PBS, and extracts were prepared in extraction
buffer (0.1 M potassium phosphate, pH 6.8/1 mM DTT). To monitor
transfection efﬁciency, pCMV-SPORT- βgal plasmid (Invitrogen Corp.)
was co-transfected in all experiments at a 1:15 dilution. Luciferase activ-
ity was measured using a PicaGene Luciferase assay system (Toyo-ink,
Tokyo, Japan) andwas normalized by the β-galactosidase activity as de-
scribed [11,18].
2.7. Chromatin immunoprecipitation (ChIP) assays
After 24 h incubation with stimulants, RINm5F and 1.1B4 cells were
processed for the ChIP assay as per the protocol described previ-
ously [18] using a ChIP-IT kit (Active Motif, Carlsbad, CA) following
the manufacturer's instructions. The antibody used for the ChIP was
STAT3 antibody (SantaCruz). The sequences for rat and human HGF
gene promoters were as follows: sense primers, 5′-AGCTGGGATCT
GTTGCTTGT-3′ (for rat) and 5′-GGGATCTGTTTGGTGCTGTT-3′ (for
human) and antisense primers, 5′-ATGCCGGGCTGAAAGAATCC-3′ (for
rat) and 5′-AGTTTGGTCACCCACATGGT-3′ (for human). The PCR prod-
uctswere analyzed on2.5% agarose gel electrophoresis and documented.
3. Results
3.1. HGF attenuates the apoptosis induced by the high concentrations of
Reg I protein
We previously reported that high concentrations of Reg I protein
(300–1000 nM) induced the apoptosis of RINm5F β cells [12]. More
higher serum concentrations of Reg family protein (over 10 μM) were
reported in pathological conditions such as pancreatitis [27]. As shown
in Fig. 1A, a single addition of IL-6, Dx, NA, nor 3AB alone did not inhib-
it the apoptosis induced by 1000 nM Reg I protein. On the other hand,
the combined addition of IL-6 and Dx signiﬁcantly inhibited the apopto-
sis. The addition of PARP inhibitors, NA or 3AB, to IL-6 + Dx was inef-
fective. Moreover, the addition of 2.5 and 25 ng/ml HGF showed an
anti-apoptotic activity against the Reg I-induced apoptosis as well as
the combined addition of IL-6 + Dx. In the presence of 1000 nM Reg I
protein, the viable cell numbers were increased by the addition of IL-
6 + Dx as well as by the addition of HGF (Fig. 1B). The combined addi-
tion of IL-6 + Dx and HGF did not increase signiﬁcantly more WST-1
cleavage than the addition of IL-6 + Dx or HGF alone. These results
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Fig. 1.HGF attenuates the apoptosis induced by the high concentrations of Reg I protein in
RINm5F cells. Cells were incubated for 24 hwith rat Reg I (1000 nM), IL-6 (20 ng/ml), Dx
(100 nM), NA (10 mM), 3AB (1 mM), and HGF (2.5HGF; 2.5 ng/ml, 25HGF; 25 ng/ml).
Values are mean ± S.E. of 7 experiments. (A) Apoptosis of RINm5F cells was quantitated
by the TUNEL method. Statistical analysis was performed using student's t test. Asterisks
indicate signiﬁcant difference from the value with no addition at P b 0.001. (B) Cleavage
of WST-1 by viable cells was measured. * and #, P b 0.05 and P b 0.001 when compared
with Reg I, respectively. $ and §, P b 0.05 and P b 0.001when comparedwith no addition,
respectively.
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Fig. 2. Induction of HGF mRNA and protein by the combined addition of IL-6 + Dx.
(A) Real-time RT-PCR of HGF mRNA in RINm5F cells. RINm5F cells were treated for 24 h
with Dx, IL-6, NA or combinations thereof. All expression data were determined and
shown as means ± S.E. (n = 3–6). A representative gel image of RT-PCR of HGF is
shown as an inset ﬁgure. (B) Concentrations of HGF protein in the RINm5F medium
weremeasured. TheHGF concentrations of theRINm5F cell culturemedium innoaddition
control, IL-6, and Dxwere less than 0.2 ng/ml. Values are mean ± S.E. of triplicate exper-
iments. (C) Induction of HGF mRNA in primary cultured islets by RT-PCR. Rat islets were
incubated in the presence or absence of the mixture of IL-6 + Dx for 24 h. Relative HGF
mRNA was increased to 4.59 ± 0.84 folds in IL-6 + Dx treated islets compared to that
of untreated (control) islets (n = 3; P = 0.0276).
2990 K. Nakagawa et al. / Biochimica et Biophysica Acta 1833 (2013) 2988–2995suggest that HGF is induced and secreted from pancreatic β cells by the
combined addition of IL-6 + Dx to protect the Reg I-induced apoptosis.3.2. Induction of HGF by the combined addition of IL-6 + Dx
We then analyzed the HGF gene expression in RINm5F cells by RT-
PCR. The combined addition of IL-6 + Dx induced the expression of
HGF mRNA (Fig. 2A), whereas the addition of IL-6, Dx, nor NA alone
did not induce the HGF mRNA expression. A little increase of the
mRNA was observed by the combined addition of IL-6 + Dx + NA. In
the RINm5F culture medium, signiﬁcantly higher concentrations of
HGF were detected with the combined addition of IL-6 + Dx (Fig. 2B).
We also performed RT-PCR analysis with isolated rat islets. The com-
bined addition of IL-6 + Dx induced theHGFmRNA expression in islets
and a representative photograph of RT-PCRwas shown in Fig. 2C. These
results indicate that pancreatic β cells express HGF mRNA and secreteHGF protein in response to the inﬂammatory stimuli such as the com-
bined stimulation of IL-6 and glucocorticoids.
3.3. Activation of the HGF promoter by IL-6 + Dx
To determine whether the increase of HGFmRNAwas caused by the
activation of transcription, a 1395-bp fragment containing 1336 bp of
the promoter region of the rat HGF gene was fused to the luciferase
gene and transfected it into RIN5mF cells. The combined addition of
IL-6 + Dx markedly increased the relative luciferase activity, whereas
IL-6, Dx, NA, 3AB alone, IL-6 + NA, IL-6 + 3AB, Dx + NA nor Dx +
3AB was ineffective. The addition of PARP inhibitors to the combina-
tion of IL-6 + Dx did not additionally increase the promoter activity
(Fig. 3A). These promoter assays revealed that the induction of the
HGFmRNAoccurred at the transcriptional level.Wepreviously reported
that the combined addition of IL-6/Dx induced the Reg I gene activation
in RINm5F cells [11]. To investigate whether the HGF promoter was ac-
tivated by Reg I protein in RINm5F cell culture medium, we added
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Fig. 3. The ratHGF promoter activity in RINm5F cells. (A) Induction of theHGF promoter by IL-6 + Dx. The promoter activity was normalized for variations in transfection efﬁciency using
β-galactosidase activity as an internal standard and was expressed relative to the activity of pGL3-Basic. Values are mean ± S.E. of triplicate experiments. (B) Reg I protein did not induce
theHGF promoter activation. The promoter activity was expressed relative to the activity of the reporter plasmid containing the full length of the HGF promoter (−1336 to+59) with no
addition. Values are mean ± S.E. of triplicate experiments.
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um and analyzed the HGF promoter activity. As shown in Fig. 3B, the
addition of Reg I protein did not activate the HGF transcription. These
results indicate that theHGF promoter activation by the combined addi-
tion of IL-6 + Dx is not mediated by Reg I protein in the medium and
that the promoters for HGF and Reg I are independently activated by
the combined addition of IL-6 + Dx in pancreatic β cells.
3.4. Localization of IL-6/Dx-responsive region in the HGF promoter
In order to identify the region necessary for the induction of theHGF
gene by IL-6 + Dx, progressive deletions of the HGF promoter were
performed. The deletion down to position−96 did not alter signiﬁcant-
ly the expression of the reporter gene induced by the combined addition
of IL-6 + Dx, but an additional deletion to nucleotide −92 caused aremarkable decrease of promoter activity (Fig. 4A), indicating that
the region from −96 to −92 is essential for the IL-6 + Dx-sensitive
HGF promoter activities. The 5′-upstream region of the rat HGF gene
(−148 to −1) was highly conserved in human (94.6%), mouse
(98.0%), and chicken (79.2%) HGF genes. A computer-aided search for
sequences similar to known cis-acting elements revealed that there
were four possible binding sites for transcription factors: signal trans-
ducer activator of the transcription family (STATx), nuclear respiratory
factor 2 (Nrf-2), GATA transcription factor (GATA), and heart shock fac-
tor 2 (HSF-2) (Fig. 4B).
3.5. STAT3 is a key factor for HGF transcription
To map out the cis-elements of HGF promoter that are responsible
for the IL-6 + Dx-induced HGF transcription, site-directedmutagenesis
AB
Fig. 4. Localization of IL-6/Dx-responsive region in theHGF promoter. (A) The promoter activity on deleted promoter of ratHGF gene. A series of luciferase constructs containing promoter
fragmentswith various 5′-endswere transfected into RINm5F cells. The promoter activitywas normalized andwas expressed relative to the activity of pGL3-Basic. Values aremean ± S.E.
of triplicate experiments. (B) Alignment of the 5′-ﬂanking regions of rat (D14341), human (M75967), mouse (L25131), and chicken (AADN01083937) HGF genes. Residues that are con-
served among all the genes are designated by asterisks. Residues that are conserved between 3 of 4 genes are designated by dots. Possible binding sites for transcription factors in the
promoter region of−96 construct were underlined and labeled.
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the luciferase construct of “−1336”. STAT-M1,which altered STAT bind-
ingmotif, STAT-M2,which altered bindingmotifs of STAT andNrf-2, and
GATA-M, which destroyed binding motifs of GATA and HSF-2 were
constructed (Fig. 5A). As shown in Fig. 5B, STAT-M1 and STAT-M2
showed remarkable reductions in promoter activities and GATA-M
showed almost the same promoter activity as that of−1136 construct.
Comparison between STAT-M1 and STAT-M2 showed that STAT-M2 did
not cause a further decrease of the HGF promoter activity, despite of ad-
ditional mutation in Nrf-2 binding site, indicating that the STAT binding
element (Figs. 4B and 5A) is the most important for the HGF transcrip-
tional activation by the combined stimulation of IL-6 + Dx.
To investigate speciﬁc binding of STAT transcription factor (STAT3)
to potential STAT binding element in vivo, we used ChIP assays to iden-
tify the binding state of STAT3 to the predicted STAT3 binding element
in the HGF promoter in rat RINm5F and human 1.1B4 β cells after IL-
6 + Dx treatment. As shown in Fig. 6A, the in vivo physical interactionof STAT3 to the ratHGF promoter in response to the IL-6 + Dx stimula-
tion was demonstrated. Further increment of STAT3 binding by IL-
6 + Dx + NA was not observed, which is completely consistent with
the results of promoter assays. The induction of HGF mRNA by IL-
6 + Dx was also demonstrated in human 1.1B4 β cells by real-time
RT-PCR (Fig. 6B). Furthermore, in vivo physical interaction of STAT3 to
the STAT binding element of the human HGF promoter was conﬁrmed
in human 1.1B4 pancreatic β cell line (Fig. 6C).
These data provided evidence that STAT3 bound to theHGF promot-
er and regulated transcription in pancreatic β cells in response to in-
ﬂammatory stimulus such as IL-6 + Dx treatment, and this regulation
was most likely mediated via the STAT binding site of HGF promoter.
4. Discussion
In the respect of the pathogenesis of type 1 diabetes, the extensive
destruction and depletion of β cells, their treatment should be based
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Fig. 5. Effects of site-directed mutations on the HGF promoter activity. (A) Three site-directed mutations, STAT-M1 (destroyed STAT), STAT-M2 (destroyed STAT and Nrf-2) and GATA-M
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regeneration of β cells [2]. Reg I has been demonstrated to proliferate
and/or regenerateβ cells to ameliorate animalmodels of type 1 diabetes
[8–10] and expected to apply to the treatment of human diabetes. In
spite of its growth promoting activity on β cells, it was revealed that
high concentrations of Reg I protein induced apoptosis of β cells [12].
For the application of Reg I protein to the treatment of human diabetes,
it is therefore important to use only favorable characteristics of Reg I
protein, controlling its bad side. In this study, we have demonstrated
that HGF expression was induced in rat and human β cells by the com-
bined stimulation of IL-6 + Dx and that HGF attenuated the high con-
centrations Reg I-induced apoptosis resulting in an increase of the β
cell numbers in an autocrine and/or paracrine manner.
HGF is well known as a mesenchyme-derived multifunctional pro-
tein that plays a critical role in cell survival, proliferation, migration,
and differentiation [28]. Earlier studies demonstrated that HGF receptor,
a receptor tyrosine kinase encoded by c-met proto-oncogene, was
expressed in various cells of epithelial origin including pancreatic
β cells [29,30]. HGF is also shown to promote β cell differentiation,
proliferation, and regeneration [29,30] and to increase the expression
of REG Iα mRNA in human fetal pancreatic cells [31]. Transgenic mice
overexpressing HGF in β cells resisted the diabetogenic effects ofstreptozotocin [14] and administrations of HGF expression vectors at-
tenuated β cell destruction and hyperglycemia [32]. Intraperitoneal
injection of HGF also exhibited a favorable effect for amelioration of hy-
perglycemia in diabetic mice receiving a marginal mass of islet grafts
[33]. These observations led us to speculate that HGF might play a crit-
ical role in promotingβ cell survival after injurious stimuli.When β cells
receive injurious stimuli such as inﬂammation, Reg I gene transcription
initiates via IL-6 + glucocorticoids [11] and islets could recover their
cell mass by proliferation/regeneration of β cells by Reg I protein.
Promoters for HGF gene were also activated by the combined addition
of IL-6 + Dx in β cells. This means β cells produce both Reg I and HGF
under inﬂammatory situations such as in 90% pancreatectomy and
in autoimmune models of diabetes [5,34]. Thus, HGF could enhance
the Reg I-induced proliferation/regeneration of β cells efﬁciently by
inhibiting the high concentrations of Reg I-induced apoptosis. As HGF
attenuates the Reg I-induced apoptosis, administration of HGF protein
or introduction of HGF expression vector seems to have an immediate
effect on efﬁcient Reg I-induced β cell regeneration. However, exoge-
nous HGF protein has a very short half-life in blood circulation, presum-
ably owing to its rapid clearance by the liver in vivo [35]. Although
recent progress of viral gene delivery systems [15] has enabled a
prolonged expression of foreign genes, the foreign gene expression is
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the DNA fragment ampliﬁed from the extracts before immunoprecipitation. In the control
immunoglobulin G (IgG) reaction, PCR was done in the eluates from beads collected after
preclearing of these extracts with normal rabbit serum. (B) Real-time RT-PCR of human
HGF mRNA. 1.1B4 cells were treated for 24 h with Dx, IL-6 or combinations thereof. All
expression data were determined and shown as means ± S.E. (n = 4). (C) ChIP assay
showing IL-6 + Dx increases in STAT3 binding to the HGF promoter. Nuclear proteins
bound to genomic DNA in 1.1B4 cells were cross-linked and subjected to a ChIP assay
using an antibody against STAT3, and oligonucleotide primers to PCR amplify the
human HGF promoter. Input row was the DNA fragment ampliﬁed from the extracts be-
fore immunoprecipitation. In the control immunoglobulin G (IgG) reaction, PCR was
done in the eluates from beads collected after preclearing of these extracts with normal
rabbit serum.
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strong antigenicity and cytotoxicity. Therefore, the activation of endog-
enous HGF gene should be ideal. Our ﬁndings that the combined stimu-
lation of IL-6 + Dx induces endogenous genes for Reg I and HGF in β
cells therefore may provide a new strategy for inducing the growth of
the β cell mass to ameliorate diabetes mellitus.
Up-regulation/down-regulation ofHGFmRNA and regulation ofHGF
promoter have been analyzed in a variety cells [36], however the induc-
tionHGFmRNA in pancreaticβ cells has not been reported. In this study,
we revealed the activation of the HGF gene in β cells by IL-6 + Dx pos-
sibly via involvement of STAT3. We have previously found that PARP
inhibitors enhanced the Reg I gene expression induced by IL-6 + Dx
[11]. However, the results of luciferase assays showed that PARP inhib-
itors did not activate HGF promoter. Furthermore, the cis-elements of
HGF promoter were different from that of the Reg I promoter; PossiblePARP binding sequence, which was found in rat Reg I promoter [11],
is not found in HGF promoters (Fig. 4B). These results indicate that
the transcriptional mechanisms of HGF and Reg I genes are distinct
from each other, although their activation occurs simultaneously by
IL-6 + Dx. The simultaneous expression of Reg I and HGF in β cells
raises a hypothesis that Reg I, induced by IL-6 + Dx, but not IL-
6 + Dx activates the HGF promoter or vice versa. The earlier study
that HGF increased the REG Iα mRNA in human fetal pancreatic cells
[29] seems to support this idea. However, in addition to the ineffe-
ctiveness of Reg I protein on the HGF promoter activation (Fig. 3B), rat
Reg I promoter (−2303 to +25) was not activated by the stimulation
of HGF (5 to 25 ng/ml) (data not shown), suggesting that these two
genes are independently activated by IL-6 + Dx through different in-
tracellular mechanisms.
In the present study, it was revealed that both Dx and IL-6 was re-
quired for HGF transcription in pancreatic β cells via STAT3 activation.
Requirement of both IL-6 and Dx for STAT3 activationwas also reported
in rat serine protease inhibitor-3 gene transcription [37]. However, in
most cases, IL-6 induces STAT(3) activation and glucocorticoids such
as Dx suppresses STAT(3) activation [38]. Although why glucocorticoid
is required for STAT3 activation in addition to IL-6 remains unknown, si-
multaneous transcriptional activation of HGF and Reg I by the combined
addition of IL-6 and Dx in pancreatic β cells may be a novel β cell regen-
eration strategy/therapy.
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